eCompliance is a biometric tracking technology. Whenever a patient takes a dose, visits a center or meets a community healthcare worker (CHW), both have to give their fingerprint or an iris scan. This registers their presence/meeting, time and GPS location. The application sends the data to a central server regularly. There is real time information if a patient has missed a dose so that the CHW can immediately follow up and visit the patient to administer the medicine. This ensures that every dose is taken, thus ‘turning the tap off’ on drug resistant tuberculosis (TB). eCompliance has been rolled out for nearly 50,000 TB patients in nine countries. It has recorded over 2.25 million transactions.
This application was developed to improve the treatment success rate of TB patients. Evidence in support of Operation ASHA’s model and technology:
Harvard Business School and the World Bank completed a randomized controlled trial (RCT) on effectiveness of eCompliance technology recently. They found the drop-out rate (or default, which leads to drug-resistance) is lower by 25% among patients treated with eCompliance, compared to others. This was a large, rigorous RCT involving thousands of patients in four states in India. It lasted for three years.
The Country Director of the World Bank in India wrote that “If Operation ASHA could be rolled out everywhere TB is, we could stop multi-drug-resistant TB and save so many lives. What Operation ASHA does is bridge the gap for the elusive last mile in service delivery – the mile that lies in between well-intended government programs and results on the ground. And they do it with relentless focus and incredible efficiency. What if we could develop Operation ASHA for other problems as well. It would be incredible.”
In the future, we would like to expand within India and in Asia and Africa, mainly within the 30 high burden countries for TB identified by the WHO.
Main Target Group
TB patients and other NGOs
Price (in USD)
$3.50 (cost per patient)
In this place, an external content of Vimeo / YouTube can be displayed.